TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Apresentado sáb., 7 de nov. · 09:00 GMT-6LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark TrialsTodos os ensaios Late-Breaking Science →

Lp(a)HORIZON extended analyses

2026

Extended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)HORIZON Trial

In patients with established cardiovascular disease and high lipoprotein(a), pelacarsen was not associated with fewer major adverse cardiovascular events across on-treatment, total-event, landmark and subgroup analyses compared with placebo.

Resultado

Eficácia: Cardiovascular outcomes beyond the primary analysis (not specified before the presentation)hazard ratio 0,98 (IC 95% 0,85-1,12)

Abaixo de 1 a favor de pelacarsen, acima de 1 a favor de placebo.

Taxas de eventos
Diferença absoluta
1,3 pontos

A diferença absoluta deriva das taxas de eventos.

Também relatado: With uninterrupted treatment, 167 (11.0%) vs 204 (10.1%) (hazard ratio 1.09; 95% CI 0.89-1.34). Total primary end point events were 644 vs 646 (rate ratio 1.00; 95% CI 0.87-1.14). In 3-month landmark analyses there was no association with the primary end point in participants with a lipoprotein(a) reduction at or above the median of 170 nmol/l (hazard ratio 1.09; 95% CI 0.92-1.29) or with an achieved lipoprotein(a) at or below the median of 69.5 nmol/l (hazard ratio 1.10; 95% CI 0.93-1.29). There was no association in any key subgroup by median baseline lipoprotein(a), LDL cholesterol, high-sensitivity CRP or time from qualifying event to enrolment.

Publicação original
Subtema
Lipoprotein(a)
Desenho
Further cardiovascular outcome analyses of Lp(a)HORIZON (randomised, double-blind, pelacarsen 80 mg monthly versus placebo)
Incluídos
8323 doentes
Fonte
Nissen SE, Cho L, et al. NEJM Evid. 2026; published online 7 November.doi 10.1056/EVIDoa2600373

Discussão e crítica

These analyses test whether the neutral primary result of the trial could be explained by drug exposure, recurrent events, the degree of lipoprotein(a) lowering or patient subgroups, and none showed a reduction in major adverse cardiovascular events with pelacarsen. On-treatment, uninterrupted treatment and landmark analyses select participants after randomisation, so they are exploratory and open to bias, though their consistency with the primary analysis strengthens the null conclusion. The abstract does not report follow-up duration, safety data or interaction P values for the subgroups. The population had established cardiovascular disease, so the results do not address primary prevention.